That’s a good question. When it is asked during investor calls we are given partial information or the answers is so inarticulate that you can’t make sense of it. It may require a one on one phone call with management or you might have to reach out formally. When we were first issued it we were told that it was a simple syringe stability data set that was missing and we could remedy it quickly, as the months went by that story expanded into receptor occupancy but only surface level Discussion no detail as to what the FDA was asking for.
Market Data 
Markets 
AI
